 My name is David Hawkewp. I am the Executive Director of Open Targets. The aim of Open Targets is to bring together industry and academia so that we can systematically identify and prioritise promising new targets for safe and effective medicines. We believe that partnership between industry and academia is really crucial because identifying the targets that will lead to safe and effective medicines is a big challenge. It requires combining the ability of academia to bring forward new biological discoveries with the expertise of industry in identifying which of those discoveries can make promising drug targets. Specifically, we've worked together identifying that Wernham is a potential target in oncology for micro-satholite and stable cancers and this was a target that was discovered through a sympathetic lethal screening programme that we ran with Matthew Garnett's lab at the Sanger with some detailed, informatic analysis led by Francesco Riorio, but ultimately the industry and academic team worked together to validate Wernham as a target for micro-satholite and stable cancers, building deeper understanding about the mechanism of action and identifying which part of the protein itself is responsible for the activity that can lead to synthetic lethalting. The future trends and challenges are obviously understanding disease in much finer detail at the level of individual cells, cell types and cell numbers, deconvoluting population genetics, moving away from and into areas of more diversity so that we can pinpoint more specific treatments for individuals and build towards a more personalised medicine approach. The trends that are enabling us to do that are working at large and larger scale in biobanks using more advanced informatic techniques like AIML and the challenges are doing that in an integrated way so that all the different experiments and findings that we can develop can be brought together into a framework that can allow identification and prioritisation of targets. In terms of working across boundaries, disease doesn't respect the boundaries of country or the boundaries of how we organise ourselves in terms of institutes or companies. So there are great minds everywhere in the world and we need to bring them all together to face the challenge of finding new treatments for disease. This is a big problem. It needs a multitude of approaches and thinking to solve it and we think working together across any kind of boundary whether that be international or intra-organisational will be important in bringing forward a new treatment.